News | February 11, 2022
Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
Adds five years of market exclusivity on approval
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
Subscribe To Our Newsletter & Stay Updated
